Meningococcal vaccine 134612

BIOLOGICAL2 trials

Sponsors

GlaxoSmithKline

Conditions

Infections, Meningococcal

Phase 2

Study in Adolescents/Adults to Evaluate the Persistence up to 3.5 Yrs of GSK Biologicals Meningococcal Vaccine 134612

CompletedNCT00390143

GlaxoSmithKlineInfections, Meningococcal

Start: 2007-02-28End: 2009-05-31Updated: 2016-10-25

Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.

CompletedNCT00454909

GlaxoSmithKlineInfections, Meningococcal

Start: 2007-04-23End: 2008-04-11Updated: 2018-06-08

Related Papers

Five-year Antibody Persistence and Booster Response to a Single Dose of Meningococcal A, C, W and Y Tetanus Toxoid Conjugate Vaccine in Adolescents and Young Adults: An Open, Randomized Trial.

2015-11-0125 citations